AUTHORS
Priyansh Faldu, Rania Abdelaziz2, Shraddha Patel3, Merry Nakhleh4, Muhammad Yousuf5, Yassin Bashir, MD6, Aysel Bayraktar7, Shivani Udyawar8, Kaaren Reichard, MD9, Rong He, MD10, Cinthya J. Zepeda Mendoza11, Animesh Pardanani, PhD, MBBS12, Naseema Gangat, MBBS13, Ayalew Tefferi, MD14
AFFILIATIONS
1 Mayo Clinic, Rochester, MN, United States
2 Mayo Clinic, Rochester, MN, United States
3 Mayo Clinic, Rochester, MN, United States
4 Mayo Clinic, Rochester, MN, United States
5 Mayo Clinic, Rochester, MN, United States
6 Mayo Clinic, Rochester, MN, United States
7 Mayo Clinic, Rochester, MN, United States
8 Mayo Clinic, Rochester, MN, United States
9 Mayo Clinic, Rochester, MN, United States
10 Mayo Clinic, Rochester, MN, United States
11 Mayo Clinic, Rochester, MN, United States
12 Mayo Clinic, Rochester, MN, United States
13 Mayo Clinic, Rochester, MN, United States
14 Mayo Clinic, Rochester, MN, United States
ABSTRACT
Background
Karyotype information plays an important role in risk stratification models for primary myelofibrosis (PMF). Prior studies have categorized cytogenetic abnormalities with a primary focus on broad prognostic groups; however, data regarding the distinct molecular and clinical characteristics associated with isolated cytogenetic abnormalities remain limited. In the current study, we analyzed 920 cytogenetically and molecularly-annotated patients with PMF to identify genotypic, phenotypic, and prognostic correlates of specific sole cytogenetic abnormalities.
Methods
Diagnosis of PMF was established according to International Consensus Classification criteria (Blood 2022;140:1200). Cytogenetic analysis and reporting were performed according to the International System for Human Cytogenetic Nomenclature (Cytogenet Genome Res (2024) 164 (Suppl. 1): 1–224). Normal karyotype (NK) assignment required analysis of at least 10 metaphases in the absence of clonal abnormalities. Molecular profiling was performed using a clinically validated targeted next-generation sequencing panel focused on myeloid neoplasms.
Results
A total of 920 cytogenetically evaluable patients (median age 65 years; 64% male) were included in the study. Driver mutational status included JAK2 in 545 (59%), CALR Type 1 in 183 (20%), CALR Type 2 in 25 (3%), MPL in 85 (9%), and triple-negative status in 82 (9%) patients. NK was observed in 590 (64%) patients. The most frequent sole cytogenetic abnormalities included deletion 20q in 62 (7%), deletion 13q in 48 (5%), trisomy 8 in 21 (2%), chromosome 1 translocation/duplication in 21 (2%), -Y in 15 (2%), trisomy 9 in 10 (1%), deletion 5q in 7 (1%), trisomy 21 in 6 (1%), and deletion 7q in 6 (1%) patients.
On multivariable analysis that accounted for previously established genetic and clinical risk factors and with NK as a comparator:
Del(20q) was associated with platelet count <150 x 109/L (p<0.01), palpable splenomegaly (p<0.01), and lower frequency of ASXL1 mutation (p=0.02).
Del(13q) was associated with lower frequency of ASXL1 (p<0.01) and SRSF2 (p<0.01) mutations.
Trisomy 8 was associated with anemia (p=0.05), triple-negative mutational status (p<0.01), U2AF1 S34F (p<0.01), and SRSF2 (p=0.03) mutations and lower frequency of CALR Type 1 (p=0.03) and MPL (p=0.05) mutations.
Chromosome 1 translocation/duplication was associated with peripheral blast (PB) ≥2% (p<0.01) and lower frequency of JAK2 mutation (p=0.02).
-Y was associated with older age (p<0.01), constitutional symptoms (p=0.03), and U2AF1 Q157P (p=0.03) and U2AF1 S34Y (p<0.01) mutations.
Trisomy 9 was associated with platelets <150 x 109/L (p=0.02), AMC ≥1 x 109/L (p=0.03), and JAK2 mutation (p=0.02).
Del(5q) was associated with higher leukocyte count (p=0.02) and constitutional symptoms (p=0.02). Trisomy 21 was associated with male sex (p=0.03), platelets <150 x 109/L (p=0.02), and SRSF2 mutation (p<0.01).
Del(7q) was associated with male sex (p=0.03) and leukocytes ≥11 x 109/L (p=0.04).
In univariate analysis, survival in patients with sole del(20q) (p=0.8), del(13q) (p=0.3), chromosome 1 translocation/duplication (p=0.9), trisomy 9 (p=0.3), or del(7q) (p=0.98) was similar to that of patients with NK. Furthermore, the survival similarity to NK was sustained in patients with del(20q) (p=0.7) and trisomy 9 (p=0.4) with or without one additional cytogenetic abnormality. In contrast, survival in patients with sole trisomy 8 (p<0.01; HR 2.4), -Y (p<0.01; HR 2.6), trisomy 21 (p<0.01; HR 4.4), or del(5q) (p=0.02; HR 3.2) was significantly worse than that of patients with NK. On subsequent age- and sex-adjusted analyses, these NK comparisons remained significant, except for -Y (p=0.5).
The aforementioned sole abnormalities showing inferior survival to NK displayed similar survival data to that of complex/monosomal karyotype: trisomy 8 (p=0.5), -Y (p=0.3), trisomy 21 (p=0.8), and del(5q) (p=0.95), although these comparisons were limited by small subgroup sizes. Risk of blast transformation associated with each one of the aforementioned sole abnormalities was not significantly different than that seen with NK (p>0.1 for all), except for trisomy 8 (p=0.04; HR 3.0).
Conclusion
The current study highlights distinct molecular and clinical characteristics for sole cytogenetic abnormalities in PMF and suggests that one additional cytogenetic abnormality might not undermine the previously recognized favorable prognostic impact from sole trisomy 9 or del(20q).
DISCLOSURES
Priyansh Faldu: No relevant conflicts of interest to declare.